Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Telehealth companies are split on compounded GLP-1s.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Turner, Brock E.W.
- Source:
Modern Healthcare. 9/9/2024, Vol. 54 Issue 9, p17-17. 1p.
- Subject Terms:
- Additional Information
- Abstract:
The article focuses on the advantages and disadvantages of using compounded versions of glucagon-like peptide (GLP) agonist medications being examined by weight loss-focused telehealth companies. Topics include the impact of the rising popularity of branded GLP-1 medicines, statement from Eli Lilly about compounded GLP-1s, and warning from the U.S. Food and Drug Administration (FDA) on the use of compounded drugs.
No Comments.